Population Pharmacokinetics of AZD-5847 in Adults with Tuberculosis (Abstract)
M-002
Aksana K. Jones
Population Pharmacokinetic Analysis of ABT-493 Exposures in HCV-Infected Subjects (Abstract)
M-003
Aksana K. Jones
Population Pharmacokinetics of a Pangenotypic NS5A inhibitor, ABT-530, in HCV infected Patients with and without Cirrhosis : A Pooled Analysis from Phase 2 Studies (Abstract)
M-004
Dhaval K. Shah
Understanding and Characterizing the Bystander Effect for Antibody Drug Conjugates (Abstract)
M-005
Andrew Castleman
Physiologically Based Pharmacokinetic (PBPK) Modeling of Meropenem Pharmacokinetics in Healthy and Renally Impaired Adults (Abstract)
M-006
Anuraag Kansal
Incorporation of Neuropsychiatric Inventory (NPI) Symptom Scores in an Alzheimer?s Disease Simulation Model (Abstract)
M-007
Brian Hare
PK/PD modeling predicts robust target engagement and low probability of grade 4 hematological toxicity at recommended phase 2 starting dose of VX-970 in combination with carboplatin (AUC=5) (Abstract)
M-008
Brett Howell
Mechanistic Modeling with DILIsym Predicts Species Differences in CKA via Multiple Hepatotoxicity Mechanisms (Abstract)
M-009
Christina M. Friedrich, Ph.D.
A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD) (Abstract)
M-010
Robert S. Parker
Synthesis of a Combined Neutropenia and Lymphopenia Model in Response to Chemotherapy (Abstract)
M-011
Dan Lu
Pharmacokinetics (PK) and exposure-response (E-R) analysis of Kadcyla (K) as a single agent or in combination with Perjeta (P) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease (Abstract)
M-012
Dane Kerr
A Novel PK-Target Occupancy Link Model for a Covalent and Reversible Inhibitor of Bruton Tyrosine Kinase (BTK) (Abstract)
M-013
Morris ME
A Mechanistic and Physiologically-Relevant PK/PD Model for the Drug of Abuse, -Hydroxybutyric Acid (GHB) in rats (Abstract)
M-014
Eline Van Maanen
Quantification of the modulation of Abeta oligomers following secretase inhibition - A systems pharmacology approach (Abstract)
M-015
Evan Wang
Performance Characteristics of NONMEM Parallelization (Abstract)
M-016
Felipe K. Hurtado, Ph.D.
Predicting End-of-trial Fasting Glucose and HbA1c via Mechanistic PK/PD Modeling based on Longitudinal Type 2 Diabetes Trial Data (Abstract)
M-018
Yan Feng
Identification of Time-Varying CL in Population Pharmacokinetic Analysis: CWRES plot vs. Bayesian information criterion (BIC) (Abstract)
M-019
Ihab Girgis
Challenges in Developing a Population Pharmacokinetic Model Describing the PK of Atazanavir and Supporting Dose Selection in HIV infected Pediatric Subjects (Abstract)
M-020
Akihiro Hisaka
Extensive Simulation of Various Dosages of Factor Xa Inhibitors (Rivaroxaban, Apixaban, and Edoxaban) to Optimize Therapeutic Benefit Based on Outcomes from Model-Based Meta-Analysis of Large Clinical Studies (Abstract)
M-021
Hongmei Xu
Evaluation on efficacy of EGFR tyrosine kinase inhibitors in NSCLC patients: A meta-analysis of 68 randomized clinical trials (Abstract)
M-022
Scott Siler
Mechanistic modeling of drug-induced liver injury due to mtDNA depletion in DILIsym (Abstract)
M-023
James Dunyak
Using Dose-Response Modeling to Improve Planning, Study Design, and Decision Making in Early Clinical Development (Abstract)
M-024
James Dunyak
Integrating Dose Estimation into a Decision Making Framework for Model-Based Drug Development (Abstract)
M-025
Jeffrey L. Woodhead
Providing Insight into Novel Dosing Protocols Using a QSP Model of Drug-Induced Liver Injury (Abstract)
M-026
Jennifer Sheng
Preclinical Tumor Dynamic Modeling of an Anti-Fucosyl-GM1 Antibody: Development of a Semimechanistic Model (Abstract)
M-027
Liang Zhao
Methodology Advancement on Dose-Scale Analysis to Assess Pharmacodynamic Equivalence (Abstract)
M-028
Stephan Schmidt
Development of a Universal Pharmacogenetics-guided Warfarin Dosing Nomogram (Abstract)
M-029
Gauri G. Rao
Pathogenesis of pneumonia due to Acinetobacter baumannii: Using a mechanistic model to describe the pathogen-host interaction (Abstract)
M-030
Jon Collins
Comparison of Human Tissue Exposure following Partial Destructive Sampling using Bootstrapped Non-Compartmental(NCA) Method vs Non-linear Mixed Effects Models(NLME) (Abstract)
M-031
Jonathan Paul Mochel
A first application of population pharmacokinetics in feline therapeutics (Abstract)
M-032
Justin D. Lutz
Exploration of the interplay between enterohepatic circulation (EHC) and transport: a physiologically-based pharmacokinetic (PBPK) modeling approach using pravastatin and rosuvastatin as model drugs (Abstract)
M-033
Jeff Sachs
Application of a Framework Qualifying Fit-for-Purpose Physiological Models to Drug Discovery and Development (Abstract)
M-034
Koichiro Yoneyama
Exploration of Factors Affecting the Activated Partial Thromboplastin Time and Prothrombin Time-International Normalized Ratio Using a Quantitative Systems Pharmacology Model (Abstract)
M-035
Lindsay Clegg
Systems Pharmacology of VEGF Splicing in Peripheral Artery Disease (Abstract)
M-036
Lisa O'Brien
Application of Ramucirumab Exposure-Response Modeling to Support Dose Selection for Post Marketing Studies in Patients with Gastric Cancer (Abstract)
M-037
Mahesh N. Samtani
A Comprehensive Review of Disease Progression Models (DPM) Across the Entire Spectrum of Alzheimer Dementia (AD) (Abstract)
M-038
Malek Okour
A pharmacokinetic model for drugs undergoing enterohepatic circulation: A sensitivity analysis (Abstract)
M-039
Matthew Rosebraugh
Model Based Meta-Analysis of Efficacy in Multiple Sclerosis for Disability Progression Incidence (Abstract)
M-040
Max Tsai
Interactive Shiny Application for Exploratory Data Analysis and Simple Sampling Strategy of Pharmacokinetic Data (Abstract)
M-041
Jrgen Venitz
Using semi-PBPK modeling to explore the impact of route of administration on the metabolic drug-drug interaction (DDI) between midazolam (MDZ) and erythromycin (ERY) (Abstract)
M-042
Michael Monine
A physiological-based pharmacokinetic (PBPK) modeling framework to predict antisense oligonucleotide (ASO) distribution in the central nervous system (CNS) (Abstract)
M-043
David Tenero
Predicting Clinical Doses Based on Exposure-Response Modeling of Static Time-Kill Data (Abstract)
M-044
Alanna Ocampo-Pelland
Extension of Multi-Scale Systems Pharmacology Model (MSPM) to Evaluate Effect of Vitamin D3 (D3) Pharmacokinetics (PK) on Bone Health (Abstract)
M-045
Oleg Demin Jr
Prediction of treatment efficacy of direct antiviral agent combinations in chronic hepatitis C patients using quantitative systems pharmacology modeling approach (Abstract)
M-046
Pavan Vaddady
Pharmacokinetic and Pharmacodynamic Modeling of GPR40 Agonist MK-8666 Proof of Concept Data to Inform Clinical Decisions (Abstract)
M-047
Roberto Gomeni
Evaluation of beta transformation to estimate treatment effect in depression and schizophrenia trials with nonlinear mixed effects analyses (Abstract)
M-048
Renu Singh (Dhanikula)
Model Based Approach for Prediction of Human Pharmacokinetic Variability and Efficacy of an Antibody Drug Conjugate from Preclinical Data (Abstract)
M-049
Robert Fox
POP PK Quality Control: Data Proofing and Model Verification (Abstract)
M-050
Sergey Aksenov
Physiological modeling of uric acid in man: application to assess benefit-risk of lesinurad in gout (Abstract)
M-051
Shang-Chiung Chen
Population pharmacokinetics of trastuzumab emtansine (T?DM1) in patients with HER2-positive advanced gastric cancer (AGC) (Abstract)
M-052
Shijun Wang
A proof-of-principle example for identifying drug effect from a mechanistic model with a more parsimonious model (Abstract)
M-053
Lisl Shoda
Mathematical Modeling to Investigate Pleiotropic TNF- Activity in Drug Induced Liver Injury (Abstract)
M-054
Shringi Sharma
Population pharmacokinetics and exposure-response of filgotinib in patients with moderate to severe Crohns disease (Abstract)
M-055
Shuhua Hu
An efficient language for model-based trial simulations (Abstract)
M-056
Shuhua Hu
Simulation of complex population PKPD models with adaptive dosing regimens (Abstract)
M-057
Siak Leng Choi
A longitudinal PKPD model describing the static Physician Global Assessment (sPGA) Response to ixekizumab in patients with moderate to severe plaque psoriasis (Abstract)
M-058
Weirong Wang
Working Towards a Physiologically-based Mathematical Model for Predicting Treatment Outcomes in a Prostate Cancer Mouse Model (Abstract)
M-059
Weirong Wang
Mechanistic Understanding of the Impact of Loading Dose in the antiTNF Biologics Treatment of Inflammatory Bowel Disease in an Adoptive T cell Transfer Mouse Model (Abstract)
M-060
Stephan Schmidt
Development of an Integrated Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin and Erythromycin in Healthy Subjects (Abstract)
M-061
Mirjam N Trame
A Quantitative Systems Pharmacology Model to Predict the Effects of Warfarin, Rivaroxaban and Enoxaparin on the Human Coagulation Network (Abstract)
M-062
Takayo Ueno
Safety Exposure-Response Analysis for Daclatasvir/Asunaprevir/Beclabuvir Regimen in Hepatitis C Virus Infected Subjects (Abstract)
M-063
Takayo Ueno
Efficacy Exposure-Response Analysis for Daclatasvir/Asunaprevir/Beclabuvir Regimen in Hepatitis C Virus Infected Subjects (Abstract)
M-064
Yan Ji
PK/PD Modeling of Soluble Ligand and Tumor Growth Inhibition for Anti-GITR Antibody mDTA-1 in Syngeneic Mouse Tumor Models (Abstract)
M-065
Tatiana Karelina
Quantitative systems pharmacology model of amyloid pathology allows for clinical endpoint prediction and hypothesis testing (Abstract)
M-066
TJ Carrothers
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis (Abstract)
M-067
Benjamin Weber
Relationship between nintedanib exposure, clinical efficacy and adverse events in patients with idiopathic pulmonary fibrosis (IPF) (Abstract)
M-068
Wangda Zhou
Development of a Physiologically Based Pharmacokinetic Model to Predict the Exposure of Itopride in Flavin-Containing Monooxygenase 3 Extensive and Poor Metabolisers (Abstract)
M-069
Wangda Zhou
Application of Physiologically Based Pharmacokinetic Modeling to Predict Raltegravir Pharmacokinetics in Children (Abstract)
M-070
M Rose Feng
Population Pharmacokinetics and Pharmacodynamics of Bivalirudin in Chinese Subjects (Abstract)
M-071
M Rose Feng
Population Pharmacokinetics and Dose Proportionality of Aranidipine Sustained-release Capsules in Healthy Subjects (Abstract)
M-072
Xiao Hu
Development of Time to Event Models for Exposure-Response Analysis of Peginterferon Beta-1a in Subjects with Relapsing Remitting Multiple Sclerosis (Abstract)
M-073
Xiao-Xing Wang
Population Pharmacokinetics and Food Effect of the Antihypertensive Drug Aranidipine in Healthy Subjects (Abstracts)
M-074
Xiao-Xing Wang
Semi-Mechanistic Physiologically-Based Pharmacokinetic Modeling of L-Histidine Disposition and Brain Uptake in Wildtype and Pht1 Null Mice (Abstract)
M-075
William J Jusko
Mathematical modeling of temporal proteomic profiles in response to gemcitabine on pancreatic cancer cells (Abstract)
M-076
Steven Xu
Covariate Test Using Empirical Bayes Estimates May be better than Likelihood Ratio Test for Population Pharmacokinetic Modeling: Why We Don?t Have to be Concerned about Shrinkage (too much) (Abstract)
M-077
Rong Deng
Optimal sampling design for a pediatric pharmacokinetic study of an anti-influenza A monoclonal antibody, MHAA4549A, with prior information from adults (Abstract)
M-078
Yeshitila Gebremichael
Development of a quantitative systems pharmacology model of druginduced renal proximal tubule injury for benchmarking and translation (Abstract)
M-079
Ying Hong
Population PK-tumor size dynamic modeling and survival analysis of EGF816, a third generation, mutant-selective EGFR TKI, in patients with advanced NSCLC harboring T790M (Abstract)
M-080
Yougan Cheng
Development of a Quantitative Systems Pharmacology (QSP) Toolbox and Virtual Population (VPop) for Affinity-Drug Conjugate (ADC) Research (Abstract)
M-081
Dinko Rekic
A Disease Progression Model of Longitudinal Lung Function Decline in Idiopathic Pulmonary Lung Fibrosis Patients (Abstract)
M-082
Guohua An
A Semi-mechanistic Pharmacokinetic-Enzyme Turnover Model for Dichloroacetic Acid Auto-inhibition in Rats (Abstract)
Tuesday
T-001
Yanguang Cao
A Multiscale Physiologically Based Pharmacokinetic Model for Doxorubicin: Scale-up from Mouse to Human (Abstract)
T-002
Yi Wang
Exposure-Response Analyses of C1 Esterase Inhibitor in Adult and Pediatric Patients for the Prevention and Treatment of Hereditary Angioedema Attacks (Abstract)
T-003
Ajit Chavan
Exposure-Response Analyses to Assess Lack of QT Prolongation by VS- 6063 in Healthy Subjects or in Patients with non-Hematologic Malignancies (Abstract)
T-004
Akihiro Hisaka
Proper Number of Subjects and Study Design for Evaluation of Ethnic Difference of Oral Clearance: Use of Inter-individual and Inter-study Variability Obtained from Meta-analysis (Abstract)
T-005
Anasuya Hazra
Tofacitinib Dose Selection by Extrapolation of Efficacy from Adult RA to Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Optimal Design to Select PK Sampling Times for a Phase 3 (P3) Study in Children (Abstract)
T-006
Yanguang Cao
A Minimal Physiologically-Based Pharmacokinetic Model to Investigate FcRn-Mediated mAb Recycling: Effect of Kon, Koff, Endosome Trafficking, and Animal Species (Abstract)
T-007
Chanchala Kaddi
QSP model of Niemann Pick B Disease and Olipudase Alpha ERT is an innovative tool for extending the value of clinical data and disease knowledge, and filling the gap through computer simulation (Abstract)
T-008
Chao Xu
A continuous-time Markov model to describe the occurrence and change in severity of diarrhea events over time in metastatic breast cancer patients treated with Lumretuzumab in combination with Perjeta and Paclitaxel (Abstract)
T-009
William R. Gillespie
Stan Functions for Bayesian Pharmacometric Modeling (Abstract)
T-010
Anna Schwendeman
Indirect response model for pharmacokinetic-pharmacodynamic (PK/PD) relationship between synthetic high density lipoprotein (sHDL) and cholesterol efflux (Abstract)
T-011
Dong-seok Yim
Evalulation of parallel efficiency for NONMEM, using multi-core processors and Intel Xeon Phi Co-processors (Abstract)
T-012
Farzaneh Salem
Does birth have an effect on UGT2B7 activity in neonates? (Abstract)
T-013
Kairui Feng
Performance and Scalability of Parallel Computing in Biosimulation/modeling Platforms for Pharmacometric Solutions (Abstract)
T-014
Helena Edlund
Comparison of estimation methods for modelling aggregated survival data (Abstract)
T-015
Robert C. Penland
The impact of modelling and simulation in oncology: a survey of all drugs approved in oncology by the FDA 2005-2015 (Abstract)
T-016
Helene Chapy
Evaluation of body weight descriptors in modeling of cefoxitin and cefazolin pharmacokinetics in the normal and obese populations (Abstract)
T-017
Herbert Struemper
Population Pharmacokinetics and Exposure-Response Relationships of Belimumab Following Subcutaneous Administration in Subjects with Systemic Lupus Erythematosus (Abstract)
T-018
Yanguang Cao
Maximum Tolerated Dose or Low-Dose Metronomic Regimen: Implication by A Cellular Pharmacodynamics Model Based on in vitro Cytotoxic Data (Abstract)
T-019
Iraj Hosseini
Systems Pharmacology Modeling to Support Clinical Development of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody (Abstract)
T-020
J. Zhang
Prediction of SVR rates in HCV GT-3 non-cirrhotic patients with 8 weeks of Daclatasvir + Sofosbuvir Ribavirin treatment using a viral kinetics model (Abstract)
T-021
J.G.C. van Hasselt
Predicting kinase inhibitor induced cardiotoxicity using transcriptomics and clinical risk scores (Abstract)
T-022
Joyce S. Macwan
Prediction of Metabolic Interactions with Atazanavir through UGT1A1 Inhibition using a Physiologically Based Pharmacokinetic Model (Abstract)
T-023
Rajendra P. Singh
Population Pharmacokinetics of Trametinib in Combination with Continuous or Intermittent Dosing of a PI3K inhibitor, GSK2126458 in Patients with Advanced Solid Tumors (Abstract)
T-024
Mindy H Magee
Population Pharmacokinetics/Pharmacodynamics of anti-beta-Amyloid Monoclonal (BAM) Antibody GSK933776 in Patients with Geographic Atrophy Secondary to Age related Macular Degeneration (Abstract)
T-025
Cynthia J. Musante
Model of energy balance predicts body weight and food intake in obesity/diabetes clinical trials (Abstract)
T-026
Yi Wang
Population PK and Exposure-Response Analyses of Icatibant in Pediatric Patients for the Treatment of Hereditary Angioedema (Abstract)
T-027
Jianguo Li
Evaluation of Power of Linear Mixed Effect (LME) and Linear Median Quantile Mixed (LMQM) Modeling to Predict Through-QT (TQT) Study Outcomes Using a Single Dose Arm (SDA) Data of Phase I Studies (Abstract)
T-028
Jianguo Li
Population Pharmacokinetic (PK) and Exposure Simulation Analyses for Cediranib (AZD2171) in Pooled Phase I/II Studies in Patients with Cancer (Abstract)
T-029
Jing Li
PK/PD model of plasma ceramide in patients with acid sphingomyelinase deficiency following enzyme replacement therapy with olipudase alfa (Abstract)
T-031
Johanna Melin
Pharmacokinetic/pharmacodynamics analysis of hydrocortisone in pediatric patients with congenital adrenal hyperplasia (Abstract)
T-032
Jonathan Chard
Pharmacometrics “Thoughtflow”: Standards for provenance capture and workflow definition (Abstract)
T-033
Jos Lommerse
Raltegravir PK in neonates - An adaptive trial design to define an appropriate regimen for neonates from birth to 6 weeks of age. (Abstract)
T-034
Jos Lommerse
Raltegravir PK in neonates - Modeling rising and declining PK profiles of newborns exposed to raltegravir in-utero (Abstract)
T-035
Jun Chen
Use of PBPK Modeling to Identify Unexpected Ferroquine Pharmacokinetics in a Phase 1 Study and to Support a Phase IIb Study (Abstract)
T-036
Justin D. Lutz
A Pharmacokinetic-Pharmacodynamic (PKPD) Model Describing Irreversible Inhibition of Bruton?s Tyrosine Kinase by GS-4059 (Abstract)
T-037
Justin D. Lutz
A mechanistic model describing the effect of respiratory syncytial virus (RSV) kinetics on clinical symptom score, and disease attenuation by presatovir (GS-5806) (Abstract)
T-038
Lanyi Xie
Application of A Physiologically-Based Subcutaneous Absorption Model to Estimate Bioavailability of Monoclonal Antibodies Using Subcutaneous Data Only (Abstract)
T-039
Li Zhang
Model-based Meta-analysis of Bortezomib Exposure - Response Relationships in Multiple Myeloma Patients (Abstract)
T-040
Li Zhang
Model-based Meta-analysis of GLP-1 Agonist Liraglutide Intervention of Obesity and Glucose Intolerance Disease Progression in Type 2 Diabetes (Abstract)
T-041
Songmao Zheng
A mathematical model of tumor-immune interactions for evaluating mono- and combination cancer immunotherapy (Abstract)
T-042
Lora Hamuro
Modeling and Simulation of the Six Minute Walk Test (6MWT) during Disease Progression in Duchenne Muscular Dystrophy (DMD) (Abstract)
T-043
Ihab Girgis
Leveraging Pharmacometrics in Selecting Proper Dose Regime for Nulojix in Pediatric Patients (Abstract)
T-044
Markus Krauss
A Systems Pharmacology Approach for Translational Learning and Pharmakokinetic Predictions across Patient Populations (Abstract)
T-045
Matts Kgedal
Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses: a simulation study (Abstract)
T-046
Dean Bottino
Identifying Optimal Dose Combinations of Anticancer Agents via Simultaneous Clinical Exposure-Toxicity and Preclinical ExposureEfficacy Modeling (Abstract)
T-047
Allan Rae
Development of an interactive tool to explore pediatric doses and sample size for pediatric trials (Abstract)
T-048
Mikael Sunnaker
IQM Tools? Efficient State of the Art Modeling across Pharmacometrics and Systems Pharmacology (Abstract)
T-049
Melanie Wilbaux
Effect of supplemental formula milk on physiological weight changes in neonates (Abstract)
T-050
Mohamed Ismail
The Use of Animations in Describing Underlying Quantitative Systems Pharmacological Processes.(Abstract)
T-051
Murad Melhem
Automation of Population Pharmacokinetic-Pharmacodynamic Modeling Reports Using the RShiny Application: TFL Generator (Abstract)
T-052
N. Terranova
Information gain in considering individual tumor size lesion dynamics for future model developments: classification and clustering are the 1st step forward (Abstract)
T-053
Nidal Al-Huniti
Modeling of Relationships of Cediranib Exposure to Hypertension and Diarrhoea for Cediranib Phase I and II Studies in Patients with Cancer (Abstract)
T-054
Nina X. Wang
Interactive Exploration and Quality Control of NONMEM Data Using R Shiny (Abstract)
T-055
Oleg Demin
Exploration of differences between mechanism-based PK/PD and systems pharmacology models (Abstract)
T-056
Oleg Demin Jr
Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach (Abstract)
T-057
Donald E. Mager
Minimal Physiological Model of Trastuzumab and Rituximab Subcutaneous Absorption Across Species (Abstract)
T-058
Parag Garhyan
Leveraging a Quantitative Systems Pharmacology Model to Explore the Mechanism of Action of a Novel Basal Insulin Analog (Abstract)
T-059
Patanjali Ravva
Mechanistic Population Pharmacokinetics of Oseltamivir in neonates to young adult patients with normal renal function (Abstract)
T-060
Murad Melhem
Population Pharmacokinetics and Pharmacodynamics (PK/PD) of Etelcalcetide for Secondary Hyperparathyroidism (sHPT) in Subjects with Chronic Kidney Disease (CKD) on Hemodialysis (Abstract)
T-061
Steve Riley
Predictive Performance of Early Phase 1 Studies in Assessing Thorough QT Outcome Across 12 Compounds - Application of a Novel Analysis Method (Abstract)
T-062
Ramy A. Abdelrahman
Population Pharmacokinetic model of trebananib in pediatric patients with relapsed solid tumors (Abstract)
T-063
Robert Fox
Simplifying Data Builds for Pharmacometric Modeling: A Generalized Dataset Format Approach (Abstract)
T-064
Robert Fox
A Knowledge Management Solution for Pharmacometric Analysis (Abstract)
T-065
Howard Lee
A mechanistic target-mediated drug disposition model to select an optimal biweekly dosing regimen for GC1118, a novel monoclonal antibody against the epidermal growth factor receptor (Abstract)
T-066
Shinsuke Inoue
Application of Population Pharmacokinetics/Pharmacodynamics (PopPK-PD) for Selection of Optimal Dose of Amiselimod (Abstract)
T-067
Jae-Yong Chung
Physiologically Based Pharmacokinetic Modeling of Metformin and Prediction of Pharmacokinetics in Geriatric Population (Abstract)
T-068
Michelle A. Rudek
Population Pharmacokinetics and Pharmacodynamics of Sorafenib in Acute Myelogenous/B-Type leukemia Patients (Abstract)
T-069
Theodore Rieger
Predicting the safety and efficacy of inhibition of diacylglycerol transferase 2 for the treatment of non-alcoholic fatty liver disease (Abstract)
T-070
Marchand Mathilde
Population Pharmacokinetics for Atezolizumab in Cancer Patient (Abstract)
T-071
Tianli Wang
Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling and Simulation for ASP5094, an Anti-alpha-9-integrin Monoclonal Antibody in a First-in-Human Trial (Abstract)
T-072
Donald E. Mager
Network-Based Analysis of Pharmacodynamic Heterogeneity in Multiple Myeloma Cells (Abstract)
T-073
Mirjam N. Trame
Population Pharmacodynamic and Markov Modeling Approach for Clinical Trial Outcome Predictions in Anti-obesity Drug Development (Abstract)
T-074
Lanyan Fang
Use of a Model Based Approach for Evaluation of partial Area Under the Curve for Bioequivalence Assessment of Methylphenidate Transdermal products (Abstract)
T-075
Vittal Shivva
Improving priors for human mAb linear PK parameters by using halflives from pre-clinical species (Abstract)
T-076
Winnie Weng
Best Statistical Practices for Concentration-QT Modeling: Quality Assessment of ECG Data, Model Sensitivity, Specificity and Evaluation (Abstract)
T-077
Catherine M.T. Sherwin
Exploring maternal-infant linked influenza antibody kinetics using a unified population model (Abstract)
T-078
In-Jin Jang, MD, PhD
A population Pharmacokinetic Analysis of Telaprevir in Healthy Korean and Japanese Subjects (Abstract)
T-079
Catherine Sherwin
Population pharmacokinetic modeling of gentamicin in pediatric patients and assessment of age influence (Abstract)
T-080
Rui Zhu
Interactive Concentration-QTc Analysis and Automatic Report Generation Using R Shiny and Knitr (Abstract)
T-081
Chaitali Passey
Exposure Response Analysis of Safety of Elotuzumab in Patients with Multiple Myeloma (Abstract)
T-082
Eric Sobie
Integrated analysis for quantitative predictions of drug-induced toxicity (Abstract)
Wednesday
W-001
Mirjam N Trame
Repeated Dose Pharmacokinetics in Rats for Identification of Novel Drug-Induced Nephrotoxicity Biomarkers (Abstract)
W-002
Guenther Hochhaus
Evaluation of the Performance of Modified Chi Square Ratio Statistic for Cascade Impactor Profiles Equivalence Testing (Abstract)
W-003
Jim Bosley
Integrated Network Modeling for Better Novel Target Searches and Predictive Models (Abstract)
W-004
Jens Timmer
Model-optimized safe and efficacious anaemia treatment in NonSmall Cell Lung Carcinoma (Abstract)
W-005
Richard C. Brundage
A model-based pharmacokinetic/pharmacodynamic analysis of hydrocortisone, 17-hydroxyprogesterone (17OHP), and androstenedione (D4A) in children with congenital adrenal hyperplasia (CAH) (Abstract)
W-006
Akihiro Hisaka
Estimation of Pediatric Dosages Considering Rapid Development of Physiological Functions after Birth with Approximated Simple Formulae: Implementation and Comparison with Dosages Described in the Labeling (Abstract)
W-007
Alexander C. Ross
A simple PK/PD-based model for maintained self-administration of dopamine agonists in rats (Abstract)
W-008
Ali Alhadab
The pharmacodynamics of Sertraline as Anti-funga (Abstract)
W-009
Ali Alhadab
Population Pharmacokinetics of Sertraline: A Model-based MetaAnalysis(Abstract)
W-010
Withdrawn
W-011
Gilbert Koch
Characterizing effects of carbimazole on free thyroxine levels in pediatric patients with Graves’ disease (Abstract)
W-012
Christine Xu
Utility of Physiologically-Based Pharmacokinetic Model (PBPK) for Prediction of Effects of Renal Impairment: A Learn-Confirm Paradigm (Abstract)
W-013
Craig Fancourt
A PKPD Model-Based Meta-Analysis of Subcutaneously Administered Insulins in Clinical Glucose Clamp Studies (Abstract)
W-014
Sara Quinney
Physiologically Based Pharmacokinetic Modeling of Imatinib Using Simcyp (Abstract)
W-015
Devin Pastoor
GGvisualizer - a visualization toolkit to facilitate ggplot2 adoption in pharmacometrics (Abstract)
W-016
Devin Pastoor
Simulation Patterns - Techniques for Optimizing Clinical Trial Simulations using R (Abstract)
W-017
Richard Pugh
Data Science & Big Data: An Opportunity or a threat for Pharmacometrics? (Abstract)
Best Practices for Preparation of Submission Quality Data Sets for Pharmacometric Analysis (Abstract)
W-020
Robert Fox
A Browser-based NONMEM Data Specification Order Form (Abstract)
W-021
Oleg Demin
Mechanistic approach to describe multiple effects of regulatory molecules on cell dynamics process in immune response (Abstract)
W-022
Oleg Demin Jr
Immune Response Template for Quantitative Systems Pharmacology Modeling of Immunotherapy in Oncology (Abstract)
W-023
Fahima Nekka
Pharmacometrics in mHealth: the Driving Force for Patient Centered Care (Abstract)
W-024
Christophe Chassagnole
Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour (Abstract)
W-025
Giridhar S Tirucherai
A Semi-Mechanistic Binding Model for the Population Pharmacokinetics and Pharmacodynamics of BMS-986168, a Taudirected Monoclonal Antibody (Abstract)
W-026
Xu Steven Xu
Evaluation of the Relationship between Changes in PK Parameters and its Corresponding Change on Steady-State Drug Exposure (Abstract)
W-027
Brian W Corrigan
Interactive Web Applications for Clinical Trial Simulation and Reporting: R Shiny with ‘dsim’ Package for Model-based Simulation in Alzheimer’s Disease (Abstract)
W-028
Hari Shankar Mahato
Development of a translational systems physiology model of renal function in normal and diabetic mice, rats, and humans (Abstract)
W-029
Helen Moore
A New Tumor Dynamics Mathematical Model (Abstract)
W-030
Bojan Lalovic
PK - PD of Crohn’s Disease Activity Index after treatment with risankizumab, an IL-23 inhibitor (Abstract)
W-031
Jan-Frederik Schlender
Predicting morphine drug exposure in elderly using an ageinformed physiologically based pharmacokinetic approach (Abstract)
W-032
Jason Zhang
Value of Model-Based Characterization of Time-Profile of Tumor Lesion Data to Assess Treatment Effect in Patients With Non-Small Cell Lung Cancer (NSCLC) (Abstract)
W-033
Jeanne Geiser
Simulations of Dulaglutide Phase 3 Studies Using a Quantitative Systems Pharmacology Model of Diabetes (Abstract)
W-034
Jeff Sachs
Model-Based Study Design Revealing the PKPD Relationship of Pembrolizumab in the KEYNOTE-001 Melanoma Trial (Abstract)
W-035
K. Melissa Hallow, Ph.D.
Systems Modeling of the Contribution of SGLT to Sodium Handling in the Diabetic Kidney (Abstract)
W-036
John C. Panetta
Mechanistic models of the combination of sonidegib and ribociclib to treat sonic hedgehog medulloblastoma (Abstract)
W-037
Yi Wang
Population PK Analysis of C1 Esterase Inhibitor in Adult and Pediatric Patients for the Prevention and Treatment of Hereditary Angioedema Attacks (Abstract)
W-038
Julie Dumond
Exploratory Analysis of Age on Longitudinal CD4+ T-Cell Reconstitution in HIV-Infected Patients Using a Semi-mechanistic Model (Abstract)
W-039
Joannellyn Chiu
Interspecies Scaling in Pre-clinical Population Pharmacokinetics of CF-301 (Abstract)
W-040
Joy C. Hsu
Bridging from the Intravenous to Subcutaneous Formulation of Tocilizumab for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis by Leveraging Prior Pharmacometrics Knowledge (Abstract)
W-041
Joy C. Hsu
Population Pharmacokinetics and Exposure-Efficacy and Safety Analyses of Alectinib in Crizotinib-Progressed or Intolerant Population (Abstract)
W-042
Justin Penzenstadler
Evaluation of Open Source PKPD Simulators in R (Abstract)
W-043
Kavitha Bhasi
Modeling tumor progression in patients with hematologic malignancies, following Idelalisib monotherapy (Abstract)
W-044
Michael Block
Assessment of Combination Therapy Effects on Tumor Growth Using PBPK/PD Modeling (Abstract)
W-045
Larissa Wenning
Viral Dynamics Modeling and Simulation to Support Development of Grazoprevir (GZR) and Elbasvir (EBR) for Treatment of Hepatitis C (HCV) Infection (Abstract)
W-046
Lei Ma
Population Pharmacokinetics and Pharmacodynamics of the Effect of Sarilumab on DAS28-CRP in Patients With Rheumatoid Arthritis (Abstract)
W-047
Lei Ma
Population Pharmacokinetics and Pharmacodynamics of the Effect of Sarilumab on Absolute Neutrophil Counts in Patients With Rheumatoid Arthritis (Abstract)
W-048
Christopher Rubino
A Physiological-based Pharmacokinetic (PBPK) Modeling Approach to Quantifying Drug-Drug Interactions: Applications to the Development of Fenfluramine (ZX008) for Treatment of Seizures in Dravet Syndrome (DS) (Abstract)
W-049
Nitin Mehrotra
Dosing Regimen Selection under the Animal Rule for Pegfilgrastim to Treat Patients with Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) (Abstract)
W-050
Ping Ji
Dose sensitivity of pharmacokinetic difference between similar biologics with target-mediated drug disposition (Abstract)
W-051
Luann Phillips
Interactive Code for Guiding Dose Selection (Abstract)
W-052
Michael Neely
Multiple-model, AUC-guided vs. standard trough-guided vancomycin dosing in patients (Abstract)
W-053
Mirjam N Trame
A User-friendly Computational Tool to Simulate Energy Balance Components in Pharmacological Interventions (Abstract)
W-054
Nassim Djebli
Target-Mediated Drug Disposition (TMDD) Population Pharmacokinetics (PopPK) Model Using the Quasi-Steady-State (QSS) Approximation of Alirocumab in Healthy Volunteers or Patients: Pooled Analysis of Randomized Phase I/II/III Studies (Abstract)
W-055
Neeraj Gupta
Model-based meta-analysis (MBMA) for relapsed/refractory multiple myeloma (RRMM): Application of a quantitative drugindependent framework for efficient decisions in oncology drug development (Abstract)
W-056
Neeraj Gupta
Global population pharmacokinetic (PK) analysis of ixazomib, an oral proteasome inhibitor, including data from the phase 3 TOURMALINE-MM1 study: an application of model based analysis to influence posology decisions in oncology drug development (Abstract)
W-057
Donald E. Mager
Population Pharmacokinetics and Total T-cell Dynamics of a Bispecific Antibody in Cynomolgus Monkeys (Abstract)
W-058
Parviz Ghahramani
Model Evaluations in Antimicrobial Drug Development- Common Misconceptions and Best Practices (Abstract)
W-059
Parviz Ghahramani
Pharmacokinetic Indices Driving Antibacterial Efficacy of CF-301- a Novel First-In-Class Lysin (Abstract)
W-060
Peiying Zuo
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy and Hospitalized Subjects with Influenza (Abstract)
W-061
Phyllis Chan
Clinical Trial Design Based on Disease Progression and Pharmacological Effects in the Irbesartan Diabetic Nephropathy Trial (IDNT)(Abstract)
W-062
Prakash Packirisamy
An open-source platform for Sensitivity Analysis of QSP models (Abstract)
W-063
Mirjam N. Trame
Prediction of Cardiac Contractility and Hemodynamics in Conscious Dogs using Mechanism Based Platform (Abstract)
W-064
Rajendra P Singh
Population Pharmacokinetics of Dolutegravir in HIV-Infected Pediatric Subjects (Abstract)
W-065
Rajendra P Singh
Effect of Altered In Vitro Dissolution on Lamivudine, Tenofovir, and Emtricitabine Pharmacokinetic Parameters: A PBPK Model Based Simulation Study (Abstract)
W-066
Rik Schoemaker
nlmixr: an open-source package for pharmacometric modelling in R (Abstract)
W-067
Samer Mouksassi
Empowering NonModelers to query and use your Models (Abstract)
W-068
Mirjam N. Trame
Systems pharmacology analysis of oncology drug combinations to evaluate adverse events due to drug-drug interactions (Abstract)
W-069
Chanchala Kaddi
An R Shiny-based, Interactive Visualization Tool to Exploit Clinical Trial and Real World Data: Application to Acid Sphingomyelinase Deficiency and Olipudase Alfa ERT (Abstract)
W-070
Sara Soufsaf
Combination Strategies for Psychostimulant Drugs Used in ADHD (Abstract)
W-071
Soujanya Sunkaraneni
Pharmacokinetic-pharmacodynamic modeling and simulation to predict efficacy outcomes with eslicarbazepine acetate 800 mg once-daily as monotherapy for partial-onset seizures (Abstract)
W-072
Mirjam N. Trame
Development of a longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory (Abstract)
W-073
Steven Sanchez
Short-term risks involved in transitioning between two HIV treatments: predictions through a Quantitative Systems Pharmacology approach (Abstract)
W-074
Tatiana Khariton
Population PK in humans and Target Attainment Simulations for CF- 301 - a First-In-Class Antibacterial Lysin (Abstract)
W-075
Tong Lu
Joint longitudinal ordered categorical model for drug-induced diarrhea and colitis: a case example in oncology (Abstract)
W-076
Nolen Seth Berry
MAPS, an R Shiny Application, to Assist with Biosimilar Clinical Study Design (Abstract)
W-077
William S. Denney
The NCA Consortium: Standardizing Qualification of Noncompartmental Analysis (Abstract)
W-078
Jun Li
Closed-form solutions and some pharmacokinetic properties of a compartment model where endogenous input is taken into account (Abstract)
W-079
Weirong Wang
Development of a mechanism-based pharmacokinetic/target occupancy/pharmacodynamic model to characterize the effect on neutrophil count by JNJ-61610588, an anti-VISTA monoclonal antibody, in cynomolgus monkeys (Abstract)
W-080
William J. Jusko
Network Analysis of Proteomics of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells (Abstract)
W-081
Iaki F Troconiz
Systems pharmacology model describing the kinetics of insulin-like growth factors (Abstract)
